Desmopressin (DDAVP): indications and practicalities.

Authors

Eugenia Biguzzi, Alessandro Casini, Alessandra Bosch, Johanna A Kremer Hovinga, Lorenzo Alberio, Pierre Fontana, Anne Angelillo-Scherrer, Bernhard Gerber, Working Party Of Haemostasis Of The Swiss Society Of Haematology, Swiss Haemophilia Network

Published in

Swiss medical weekly. Volume 156. Pages 5030. Sep 30, 2026. Epub Sep 30, 2026.

Abstract

Desmopressin (1-deamino-8-D-arginine vasopressin, or DDAVP) is available in Switzerland for the treatment of non-severe haemophilia A and von Willebrand disease.
To provide practical guidance for the use of desmopressin in patients with non-severe haemophilia A, von Willebrand disease, bleeding disorders of unknown cause and mild platelet function disorders.
Based on the available literature and clinical experience in Switzerland, the Swiss Society of Haematology's Haemostasis Working Group and the Swiss Haemophilia Network worked together to reach a consensus on the use of desmopressin.
Desmopressin may increase and normalise factor VIII and von Willebrand factor levels in patients with non-severe haemophilia A and von Willebrand disease and can prevent or treat bleeding in patients with bleeding disorders of unknown cause and mild platelet function disorders. A desmopressin trial is recommended to verify tolerability and identify responders, as the response to the drug is not predictable based on baseline levels of factor VIII and von Willebrand factor. Previously observed side effects and current contraindications must be carefully evaluated prior to every administration.

PMID:
42896092
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.